GlassScriptPhysician profile
Darek K Eggleston
NPI 1518302850
$5,515.47
in general payments reported to CMS, 2019-2025
50 companies · $718 in 2025
The $718 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $581 · 2020: $246 · 2021: $448 · 2022: $443 · 2023: $2,622 · 2024: $458 · 2025: $718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,082 · Travel and Lodging: $1,716.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,082.33 |
| Travel and Lodging | $1,716.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Modernatx, INC. | $2,041.38 | 2023 | |
| Abbvie INC. | $456.87 | 2019-2025 | Vraylar |
| Astellas Pharma US INC | $398.26 | 2019-2025 | Veozah |
| Pfizer INC. | $325.52 | 2019-2025 | |
| Glaxosmithkline, LLC. | $297.32 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $152.88 | 2019-2025 | Evenity, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $125.89 | 2020-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $117.36 | 2020-2025 | Farxiga, Airsupra |
| Corium, LLC | $107.30 | 2022-2024 | Azstarys |
| Baxter Healthcare | $105.87 | 2023-2025 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor, Hillrom - Life 2000 Ventilation System |
| Dynavax Technologies Corporation | $101.40 | 2021-2025 | Heplisav-B |
| Novo Nordisk INC | $92.17 | 2019-2025 | Wegovy |
| Biohaven Pharmaceutical Holding Company LTD. | $86.52 | 2022 | |
| Sanofi-Aventis U.S. LLC | $85.62 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $84.56 | 2019-2023 | Trintellix |
Show all 46 companies
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darek Eggleston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.